Md Saiful Islam Khan/iStock via Getty Images
Annexon (NASDAQ:ANNX) shares traded higher on Wednesday after the company released additional data from its completed pivotal Phase 3 trial for its lead asset, ANX005, against the neurological disorder Guillain-Barré syndrome (GBS).
Early this month, citing topline results from the study, the Brisbane, California-headquartered biotech said that ANX005 at a 30 mg/kg dose reached the primary endpoint in terms of eight-week change in the GBS-disability scale over placebo.
Updated trial results shared as part of a medical event in Canada indicated on Wednesday that those on ANX005 witnessed a 2.41-fold improvement in the GBS disability scale over the period.
“These compelling data reinforce the therapeutic potential of ANX005 to be the first targeted immunotherapy treatment for GBS,” said Dr. Quazi Deen Mohammad, lead investigator and director of the National Institute of Neurosciences and Hospital in Bangladesh.